Biogen Inc. joined a consortium to build a collection of biological and medical data, where the company’s employees who had tested for and recovered from the coronavirus would be able to participate.
BioSpace Global Roundup, March 26
Antibodies, Business, Clinical Trials, Consortium, Coronavirus Disease (COVID-19) Pandemic, European Medicines Agency (EMA), European Patent Office, FDA/Regulatory, Immuno-oncology, Immunotherapeutics, Messenger RNA (mRNA) Vaccines, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Peptides, R&D, Vaccines, X-raysA recap of business developments from life sciences companies around the world, including U.K.-based Vaccitech Limited and the University of Oxford touting positive safety and efficacy trends in a mid-stage prostate cancer study.
In January 2018, it was announced that five healthcare systems were launching a not-for-profit generic drug company. That company now has a name, Civica Rx.
Pfizer Inc. signed an agreement with Allogene Therapeutics, a company formed by a consortium in which the drugmaker will hold a 25 percent stake, to further develop its allogenic CAR T cell therapy.